skip to content
Drugs for pulmonary arterial hypertension : project protocol Preview this item
ClosePreview this item
Checking...

Drugs for pulmonary arterial hypertension : project protocol

Author: Canadian Agency for Drugs and Technologies in Health,
Publisher: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, February 2014.
Series: CADTH therapeutic review, v. 2, issue 1A.
Edition/Format:   eBook : Document : English
Database:WorldCat
Summary:
CADTH will undertake a systematic review to compare the efficacy and safety of new and existing drug therapies for pulmonary arterial hypertension (PAH), and will examine their cost-effectiveness. The review will include drug therapies that are available in Canada (epoprostenol, treprostinil, bosentan, ambrisentan, macitentan, sildenafil, tadalafil) and one for which the clinical development program is advanced but  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

 

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Review
Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Canadian Agency for Drugs and Technologies in Health,
OCLC Number: 951503832
Description: 1 online resource (1 PDF file (ii, 10 pages)).
Series Title: CADTH therapeutic review, v. 2, issue 1A.
Responsibility: Canadian Agency for Drugs and Technologies in Health.

Abstract:

CADTH will undertake a systematic review to compare the efficacy and safety of new and existing drug therapies for pulmonary arterial hypertension (PAH), and will examine their cost-effectiveness. The review will include drug therapies that are available in Canada (epoprostenol, treprostinil, bosentan, ambrisentan, macitentan, sildenafil, tadalafil) and one for which the clinical development program is advanced but is not yet approved for the treatment of PAH in Canada (riociguat). The clinical and cost-effectiveness evidence will be reviewed by the Canadian Drug Expert Committee (CDEC) for the purpose of making recommendations. Recommendations and advice delivered by CDEC are provided to CADTH participating jurisdictional drug programs to inform their policy decisions.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/951503832> # Drugs for pulmonary arterial hypertension : project protocol
    a schema:Book, schema:MediaObject, schema:CreativeWork ;
   library:oclcnum "951503832" ;
   library:placeOfPublication <http://id.loc.gov/vocabulary/countries/onc> ;
   schema:about <http://experiment.worldcat.org/entity/work/data/3149796235#Topic/hypertension_pulmonary_drug_therapy> ; # Hypertension, Pulmonary--drug therapy
   schema:about <http://experiment.worldcat.org/entity/work/data/3149796235#Place/canada> ; # Canada
   schema:about <http://experiment.worldcat.org/entity/work/data/3149796235#Topic/antihypertensive_agents_therapeutic_use> ; # Antihypertensive Agents--therapeutic use
   schema:about <http://experiment.worldcat.org/entity/work/data/3149796235#Topic/cost_benefit_analysis> ; # Cost-Benefit Analysis
   schema:about <http://experiment.worldcat.org/entity/work/data/3149796235#Topic/review_literature_as_topic> ; # Review Literature as Topic
   schema:about <http://experiment.worldcat.org/entity/work/data/3149796235#Topic/antihypertensive_agents_economics> ; # Antihypertensive Agents--economics
   schema:bookFormat schema:EBook ;
   schema:contributor <http://experiment.worldcat.org/entity/work/data/3149796235#Organization/canadian_agency_for_drugs_and_technologies_in_health> ; # Canadian Agency for Drugs and Technologies in Health,
   schema:datePublished "2014" ;
   schema:description "CADTH will undertake a systematic review to compare the efficacy and safety of new and existing drug therapies for pulmonary arterial hypertension (PAH), and will examine their cost-effectiveness. The review will include drug therapies that are available in Canada (epoprostenol, treprostinil, bosentan, ambrisentan, macitentan, sildenafil, tadalafil) and one for which the clinical development program is advanced but is not yet approved for the treatment of PAH in Canada (riociguat). The clinical and cost-effectiveness evidence will be reviewed by the Canadian Drug Expert Committee (CDEC) for the purpose of making recommendations. Recommendations and advice delivered by CDEC are provided to CADTH participating jurisdictional drug programs to inform their policy decisions."@en ;
   schema:exampleOfWork <http://worldcat.org/entity/work/id/3149796235> ;
   schema:genre "Review"@en ;
   schema:inLanguage "en" ;
   schema:isPartOf <http://worldcat.org/issn/1929-7440> ; # CADTH therapeutic review ;
   schema:name "Drugs for pulmonary arterial hypertension : project protocol"@en ;
   schema:productID "951503832" ;
   schema:url <http://www.ncbi.nlm.nih.gov/books/NBK355815/> ;
   wdrs:describedby <http://www.worldcat.org/title/-/oclc/951503832> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/3149796235#Organization/canadian_agency_for_drugs_and_technologies_in_health> # Canadian Agency for Drugs and Technologies in Health,
    a schema:Organization ;
   schema:name "Canadian Agency for Drugs and Technologies in Health," ;
    .

<http://experiment.worldcat.org/entity/work/data/3149796235#Topic/antihypertensive_agents_economics> # Antihypertensive Agents--economics
    a schema:Intangible ;
   schema:name "Antihypertensive Agents--economics"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/3149796235#Topic/antihypertensive_agents_therapeutic_use> # Antihypertensive Agents--therapeutic use
    a schema:Intangible ;
   schema:name "Antihypertensive Agents--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/3149796235#Topic/cost_benefit_analysis> # Cost-Benefit Analysis
    a schema:Intangible ;
   schema:name "Cost-Benefit Analysis"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/3149796235#Topic/hypertension_pulmonary_drug_therapy> # Hypertension, Pulmonary--drug therapy
    a schema:Intangible ;
   schema:name "Hypertension, Pulmonary--drug therapy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/3149796235#Topic/review_literature_as_topic> # Review Literature as Topic
    a schema:Intangible ;
   schema:name "Review Literature as Topic"@en ;
    .

<http://worldcat.org/issn/1929-7440> # CADTH therapeutic review ;
    a bgn:PublicationSeries ;
   schema:hasPart <http://www.worldcat.org/oclc/951503832> ; # Drugs for pulmonary arterial hypertension : project protocol
   schema:issn "1929-7440" ;
   schema:name "CADTH therapeutic review ;" ;
   schema:name "CADTH therapeutic review report," ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.